Aligos Therapeutics, Inc. announced that the company remains on track to complete all Phase 2-enabling activities in 2023 for ALG-055009, its thyroid hormone receptor beta (THR-ß) drug candidate for nonalcoholic steatohepatitis (NASH). Dr. Blatt will provide a corporate update and discuss the company's entire pipeline, including ALG-055009, the coronavirus protease inhibitor ALG-097558, and Aligos' hepatitis B portfolio, on January 12, 2023, at 10:30 a.m. PT during the 41st Annual JP Morgan Healthcare Conference in San Francisco. Dr. Blatt's presentation will also be posted on the Aligos website at the time of the conference.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
0.59 USD | -2.03% | +1.72% | -11.14% |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
-11.14% | 46.08M | |
+43.36% | 54.63B | |
-5.31% | 39.92B | |
+14.75% | 26.86B | |
-12.56% | 26.22B | |
-22.45% | 18.78B | |
+25.12% | 12.21B | |
+0.04% | 12.16B | |
+26.04% | 11.94B | |
-11.83% | 10.74B |
- Stock Market
- Equities
- ALGS Stock
- News Aligos Therapeutics, Inc.
- Aligos Therapeutics, Inc. on Track to Complete Phase 2-Enabling Activities in 2023 for its Clinically Validated THR-ß Drug Candidate for NASH, ALG-055009